Cardiac PET
Exploring cardiological indications in PET and PET/CT
According to the Center for Disease Control (CDC), cardiovascular disease (CVD) remains the leading cause of death and disease burden worldwide, accounting for 874,613 deaths in the United States in 2019. CVD includes coronary artery disease (CAD) and stroke. CAD is the most common type of CVD, with more than 18.2 million adults over the age of 20 living with CAD, resulting in 360,900 deaths in 20191. Stroke accounted for 1 in 6 deaths from CVD and more than 795,000 people in the United States suffer a stroke annually.2
Contact us
PETNET Solutions customer care team
email: customercare@petnetsolutions.com
phone: (877)-473-8643
PETNET Solutions Corporate Office
810 Innovation Drive
Knoxville, TN 37932 USA
Did this information help you?
“Heart Disease Facts.” Centers for Disease Control and Prevention, Centers for Disease Control and Prevention, 15 July 2022, https://www.cdc.gov/heartdisease/facts.htm.
“Stroke Facts.” Centers for Disease Control and Prevention, Centers for Disease Control and Prevention, 5 Apr. 2022, https://www.cdc.gov/stroke/facts.htm.
Skali, Hicham et al. “18F-FDG PET/CT for the assessment of myocardial sarcoidosis.” Current cardiology reports vol. 15,4 (2013): 352.
Haijiang Dai, Arsalan Abu Much, Elad Maor, Elad Asher, Arwa Younis, Yawen Xu, Yao Lu, Xinyao Liu, Jingxian Shu, Nicola Luigi Bragazzi, Global, regional, and national burden of ischaemic heart disease and its attributable risk factors, 1990–2017: results from the Global Burden of Disease Study 2017, European Heart Journal - Quality of Care and Clinical Outcomes, Volume 8, Issue 1, January 2022, Pages 50–60, https://doi.org/10.1093/ehjqcco/qcaa076
Khan, Moien Ab et al. “Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study.” Cureus vol. 12,7 e9349. 23 Jul. 2020, doi:10.7759/cureus.9349
“FDG PET for Myocardial Viability.” CMS.gov Centers for Medicare & Medicaid Services, https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=298&NCDver=1.
Al Moudi, Mansour, and Zhong-Hua Sun. “Diagnostic value of (18)F-FDG PET in the assessment of myocardial viability in coronary artery disease: A comparative study with (99m)Tc SPECT and echocardiography.” Journal of geriatric cardiology : JGC vol. 11,3 (2014): 229-36. doi:10.11909/j.issn.1671-5411.2014.03.008
Medical Advisory Secretariat. “Positron emission tomography for the assessment of myocardial viability: an evidence-based analysis.” Ontario health technology assessment series vol. 5,16 (2005): 1-167.
Caobelli, Federico, et al. “The Importance of 18F-FDG Cardiac PET/CT for the Assessment of Myocardial Viability in Ischaemic Heart Disease.” Swiss Medical Weekly, EMH Media, 5 June 2021, https://smw.ch/article/doi/smw.2021.20511.
Caobelli, Federico, et al. “The Importance of 18F-FDG Cardiac PET/CT for the Assessment of Myocardial Viability in Ischaemic Heart Disease.” Swiss Medical Weekly, EMH Media, 5 June 2021, https://smw.ch/article/doi/smw.2021.20511.
Hunold P, Jakob H, ErbelR, BarkhausenJ, and HeilmaierC. Accuracy of myocardial viability imaging by cardiac MRI and PET depending on left ventricular function. World J Cardiol. 2018;10(9):110–118. doi:10.4330/wjc.v10.i9.110
Peterson LR, Gropler RJ. Radionuclide imaging of myocardial metabolism. Circ Cardiovasc Imaging. 2010;3(2):211-222. doi:10.1161/CIRCIMAGING.109.860593
Celiker-Guler E, Ruddy TD, Wells RG. Acquisition, Processing, and Interpretation of PET 18F-FDG Viability and Inflammation Studies. Curr Cardiol Rep. 2021;23(9):124. Published 2021 Jul 16. doi:10.1007/s11886-021-01555-7
“Myocardial Perfusion Imaging.” Myocardial Perfusion Imaging - an Overview | ScienceDirect Topics, https://www.sciencedirect.com/topics/medicine-and-dentistry/myocardial-perfusion-imaging.
“Myocardial Perfusion Imaging.” Myocardial Perfusion Imaging - an Overview | ScienceDirect Topics, https://www.sciencedirect.com/topics/nursing-and-health-professions/myocardial-perfusion-imaging.
Hung GU, Wang YF, Su HY, Hsieh TC, Ko CL, Yen RF. New Trends in Radionuclide Myocardial Perfusion Imaging. Acta Cardiol Sin. 2016;32(2):156-166. doi:10.6515/acs20150803a
Yoshinaga, Keiichiro, et al. “Generator-Produced Rubidium-82 Positron Emission Tomography Myocardial Perfusion Imaging-from Basic Aspects to Clinical Applications.” Journal of Cardiology, Elsevier, 8 Feb. 2010, https://www.sciencedirect.com/science/article/pii/S0914508710000109#tbl1.
Nakazato R, Berman DS, Alexanderson E, Slomka P. Myocardial perfusion imaging with PET. Imaging Med. 2013;5(1):35-46. doi:10.2217/iim.13.1
Maddahi J, Packard RR. Cardiac PET perfusion tracers: current status and future directions. Semin Nucl Med. 2014;44(5):333-343. doi:10.1053/j.semnuclmed.2014.06.011
Fathala A, Aboulkheir M, Shoukri MM, Alsergani H. Diagnostic accuracy of 13N-ammonia myocardial perfusion imaging with PET-CT in the detection of coronary artery disease. Cardiovasc Diagn Ther. 2019;9(1):35-42. doi:10.21037/cdt.2018.10.12
Widening the Availability of Ammonia to Increase the Footprint of ... https://link.springer.com/content/pdf/10.1007/s12350-019-01986-4.pdf.
“Rubidium 82.” Rubidium 82 - an Overview | ScienceDirect Topics, https://www.sciencedirect.com/topics/medicine-and-dentistry/rubidium-82.
Chatal JF, Rouzet F, Haddad F, Bourdeau C, Mathieu C, Le Guludec D. Story of Rubidium-82 and Advantages for Myocardial Perfusion PET Imaging. Front Med (Lausanne). 2015;2:65. Published 2015 Sep 11. doi:10.3389/fmed.2015.00065